AGN
ARGENICA THERAPEUTICS LIMITED
$0.1400
▼ -6.67%
Market cap
$18M
Turnover
$774
Last price
$0.1400
Day change
-6.67%
Announcements
10
Range, past year
Open 0.265 · Low 0.087 · Now 0.140 · High 0.850
Open AGN in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
AGN momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
18/100
Wyckoff phase
Downtrend19d
Trend stage
Breakdown
1 Day
-6.7%
1 Week
-6.7%
1 Month
-30.0%
1 Year
-48.1%
RSI
40
Avg daily range
9.0%
ARGENICA THERAPEUTICS LIMITED scores 18 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 19 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -41.9%
- High volatility (ATR 9.0%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsAGN announcements
Recent price-sensitive releases.
- 2026-08-26 Appendix 4E & Annual Report to 30 June 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-24 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-16 ARG007 Shows Significant Neuroprotection in Concussion Study
- 2026-06-11 ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- 2026-06-10 WHO Confirms Xaranetide as INN for ARG-007
- 2026-05-21 IND Application Advanced With Successful Completion of Assay
- 2026-05-14 Clinical Advisory Committee Established to Advance Phase 2b
More Health Care stocks
Most traded in the same sector.